APP Receives Expedited Approval for the First and Only Generic Cefotetan Disodium for Injection (Business Wire via Yahoo! Finance)
SCHAUMBURG, Ill.----Abraxis Pharmaceutical Products , the hospital-based business of Abraxis BioScience, Inc. , today announced the approval from the U.S. Food and Drug Administration to market Cefotetan Disodium for Injection, the generic equivalent of AstraZeneca's Cefotan .

SVS Independently Validates IDBS' E-WorkBook Suite Against 21 CFR Part 11 And GLP Requirements (PharmaceuticalOnline)
IDBS, a leading Electronic Laboratory Notebook (ELN) provider, recently announced that its complete E-WorkBook Suite has been independently validated by the Sociedad de Validaci n de Sistemas (SVS) against the FDA's 21 CFR Part 11 and Good Laboratory Practice (GLP) guidelines.

Industry will have to incur GMP costs (Nutraingredients.com)
8/10/2007 - While many in the supplement and nutraceutical industry have applauded the US Food & Drug Administration's (FDA's) issuance of the long-awaited final rule to establish GMPs, not every manufacturer will be able to bear the cost of compliance with the final rule.